At the August 29 European Society of Cardiology meeting in Stockholm, results from two substudies of the PLATO study showed that, unlike clopidogrel, neither prasugrel (Effient, Lilly) nor ticagrelor (Brilinta, Asta-Zeneca) were affected by loss of function mutations of genes for enzymes in the CYP2C19 pathway. This information is likely to affect future antiplatelet drug selection regimens. Select PLATO results for details. Geo
Sep 10 2010
No comments here.